WLLW vs. HLS, TGOD, NINE, SUGR, MDP, WMD, HEXO, VIR, VM, and ZOM
Should you be buying Willow Biosciences stock or one of its competitors? The main competitors of Willow Biosciences include HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), SugarBud Craft Growers (SUGR), Medexus Pharmaceuticals (MDP), WeedMD (WMD), HEXO (HEXO), Viridium Pacific Group (VIR), Voyageur Pharmaceuticals (VM), and Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Willow Biosciences vs. Its Competitors
HLS Therapeutics (TSE:HLS) and Willow Biosciences (TSE:WLLW) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
HLS Therapeutics currently has a consensus price target of C$4.50, indicating a potential downside of 8.16%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe HLS Therapeutics is more favorable than Willow Biosciences.
HLS Therapeutics has a net margin of -38.70% compared to Willow Biosciences' net margin of -268.91%. HLS Therapeutics' return on equity of -25.27% beat Willow Biosciences' return on equity.
In the previous week, HLS Therapeutics had 1 more articles in the media than Willow Biosciences. MarketBeat recorded 1 mentions for HLS Therapeutics and 0 mentions for Willow Biosciences. HLS Therapeutics' average media sentiment score of 0.00 equaled Willow Biosciences'average media sentiment score.
65.2% of HLS Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Willow Biosciences shares are owned by institutional investors. 0.4% of HLS Therapeutics shares are owned by company insiders. Comparatively, 24.3% of Willow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Willow Biosciences has lower revenue, but higher earnings than HLS Therapeutics. Willow Biosciences is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.
HLS Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Willow Biosciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.
Summary
HLS Therapeutics beats Willow Biosciences on 9 of the 14 factors compared between the two stocks.
Get Willow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WLLW and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WLLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Willow Biosciences Competitors List
Related Companies and Tools
This page (TSE:WLLW) was last updated on 7/4/2025 by MarketBeat.com Staff
Free WLLW Stock Alerts